PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
Sign Up to like & getrecommendations! Published in 2019 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-018-0098-y
Abstract: ADJUVANT TRASTUZUMAB One year of adjuvant trastuzumab has been the standard treatment for human epidermal growth factor receptor 2positive (HER2-positive) early breast cancer since the mid2000s. From the outset, the expense and cardiac toxicity associated… read more here.
Keywords: persephone; adjuvant trastuzumab; treatment; trastuzumab ... See more keywords